Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;2(6):e286-e287.
doi: 10.1016/S2589-7500(20)30086-8. Epub 2020 Apr 24.

A real-time dashboard of clinical trials for COVID-19

Kristian Thorlund  1 , Louis Dron  1 , Jay Park  2 , Grace Hsu  1 , Jamie I Forrest  2 , Edward J Mills  1
Affiliations

A real-time dashboard of clinical trials for COVID-19

Kristian Thorlund et al. Lancet Digit Health. 2020 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Evidence network of COVID-19 clinical trials of top 15 interventions Circles (node) represent interventions or intervention groups (categories). Lines between two circles indicate comparisons in clinical trials. The numbers on the lines are the number of clinical trials making the specific comparison. Circular arrows and numbers indicate the number of non-comparative clinical trials in which that intervention is included. A few trials examining combination therapies are excluded from the figure due to space limitations. COVID-19=coronavirus disease 2019. LPV/r (lopinivir–ritonavir). *Includes trials on hydroxychloroquine and chloroquine.
See this image and copyright information in PMC

References

    1. Cao B, Wang Y, Wen D. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001282. published online March 18. - DOI - PMC - PubMed
    1. Chen J, Liu L, Liu P. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020 doi: 10.3785/j.issn.1008-9292.2020.03.03. published onlne March 6. - DOI - PMC - PubMed
    1. Chen C, Huang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020 doi: 10.1101/2020.03.17.20037432. published onine April 8. (preprint) - DOI
    1. Yao X, Ye F, Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. published online March 9. - DOI - PMC - PubMed
    1. Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105949. published online March 20. - DOI - PMC - PubMed

MeSH terms

Substances